Therapeutic Strategy of Venous Thromboembolism from the Factor of Facile Thrombosis

Abstract

Anticoagulant therapy for venous thromboembolism (VTE) is performed on cancer patients and on patients with recurrence for a longer period. It is also necessary to consider anticoagulant therapy for patients with other thrombophilic predispositions. The active cancer was diagnosed using an appropriate method. Treatment with direct oral anticoagulant was performed, and 138 patients who were able to be followed up with were classified according to the presence or absence of the factor facile thrombosis. The ratio of easy thrombotic predisposition to VTE was 39 cases 23.2%, the active cancer (CAT group) 10 cases, antiphospholipid antibody syndrome (APS group) 19 cases, protein S deficiency (PS group) 7cases, and protein C deficiency (PC group) 3 cases. In the CAT group, 4 out of 10 patients died during the follow-up period. The recurrence rate of cases with the factor of facile thrombosis was 18.7%, and the recurrence rate of cases without the factor of facile thrombosis was 7.5%. Due to tend to be high recurrence rate for the treatment of cases with the predisposition to thrombosis, it seems necessary to consider each case such as the dosing period.